
nusinersen 50 mg and 28 mg solution for injection (Spinraza®)

Biogen Idec Ltd

4 September 2026

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

nusinersen (Spinraza®) is accepted for restricted use within NHSScotland.

Indication under review: for the treatment of 5q Spinal Muscular Atrophy (SMA).

SMC restriction: patients with pre-symptomatic and symptomatic type 1 (infantile-onset) and type 2 or type 3 (later-onset) 5q SMA.

Nusinersen 50 mg and 28 mg solution for injection are indicated for a high dose regimen, with limited net budget impact compared with the 12 mg low dose regimen.

This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.

Chair
Scottish Medicines Consortium

This assessment is based on data submitted by the applicant company up to and including 01 June 2026.

Medicine prices are those available at the time the papers were issued to SMC for consideration. SMC includes Scottish national contract prices in its decision-making. These contract prices are commercial in confidence and cannot be put in the public domain, including via the SMC Detailed Advice Document.

Patient Access Schemes (PAS): A PAS is a scheme proposed by a pharmaceutical company in order to improve the cost-effectiveness of a medicine and enable patients to receive access to cost-effective innovative medicines. The Patient Access Scheme Assessment Group (PASAG), established under the auspices of Public Services Delivery Scotland, reviews and advises NHS Scotland on the feasibility and acceptability on implementing proposed schemes. PASAG operates separately from SMC to maintain the integrity and independence of the assessment process of the SMC. When SMC accepts a medicine for use in NHS Scotland on the basis of a PAS that has been considered acceptable for implementation by PASAG, a set of guidance notes on the operation of the scheme will be circulated to health boards' Area Drugs and Therapeutics Committees prior to publication of SMC advice.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration and evaluation of the available evidence. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.